Kinuya Seigo
Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641 Japan.
Nucl Med Mol Imaging. 2019 Feb;53(1):35-37. doi: 10.1007/s13139-018-0563-4. Epub 2018 Dec 15.
Targeted radionuclide therapy (TRT) is unique because of its efficacy and its theranostic feature in the era of precision medicine. So far, introduction of new TRT has not been going well in Japan due to several reasons including strict regulations, shortage of facilities for TRT, and insufficient reimbursement for TRT in clinic. Japanese community had several strategies to develop TRT in these 10 years, including the establishment of the National Conference for Nuclear Medicine Theranostics in which physicians, scientists, patients, people supporting patients, and industrial people gather. To promote TRT with supports from the government, the preparatory committee for the establishment of Japan Foundation of Medical Isotope Development (JAFMID) was launched. I would like to call TRT "Precision Nuclear Medicine." When we can add genomic information here, we can put it to new stage of cancer therapy. It is time for us.
靶向放射性核素治疗（TRT）因其疗效以及在精准医学时代的诊疗一体化特性而独具特色。到目前为止，由于包括严格的监管、TRT设施短缺以及临床中TRT报销不足等多种原因，新型TRT在日本的引入进展并不顺利。在过去十年里，日本各界采取了多种策略来发展TRT，包括成立核医学诊疗全国会议，医生、科学家、患者、患者支持者以及产业界人士齐聚于此。为在政府支持下推动TRT发展，日本医学同位素开发基金会（JAFMID）成立筹备委员会启动。我想将TRT称为“精准核医学”。当我们在此加入基因组信息时，就能将癌症治疗推向新的阶段。是我们行动的时候了。
